Systematic-Review-Drug-Efficiency-Dissertation-Sample-Work-Tutors-India
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
mark the beginning of novel therapy for IPF, more scrutiny is required to ascertain the drug<br />
efficacy as well as the effects on the reduction of mortality. Besides this, a comparative<br />
efficacy of pirfenidone in combination N-acetylcysteine can shed light on more effective<br />
treatment of IPF so as to reduce the mortality. Additionally, there is paucity in the literature<br />
that assesses the effect of these drugs on the reduction of mortality. With this view, the<br />
present study aims to assess the present evidence on the efficacy of combination therapy of<br />
pirfenidone with NAC.<br />
1.5 Research Aim and Objectives<br />
The study aims to assess the efficacy of Pirfenidone in combination with NAC. In this<br />
regard, the following objectives are framed:<br />
‣ To evaluate the efficacy of pirfenidone with NAC<br />
‣ To assess the likelihood of combination therapy in decreasing the mortality rate of<br />
IPF<br />
‣ To derive a management framework for IPF from the above and make<br />
recommendations for effective treatment<br />
1.6 Research questions<br />
1) What is the likelihood of combination therapy (pirfenidone with NAC) in<br />
decreasing the mortality rate of IPF?<br />
2) Can a management framework be derived for IPF which could recommend<br />
effective treatment of the disease using the combined drug therapy?<br />
1.7 Motivation of the Research<br />
There are several studies which evidenced the effectiveness of different drug<br />
treatment therapies for IPF wherein these evidences further enhanced the interest of<br />
researches, clinicians and patients for the treatment of the disease. IPF is no normal condition;<br />
it is a devastating disease which progresses with scar tissue deposition in the lungs which<br />
further leads to shortness of breath and at the end results in total failure of the lungs thereby<br />
leading to death. It has been documented seriously over the years that the incidence of the<br />
© 2017-2018 All Rights Reserved, No part of this document should be modified/used without prior consent<br />
<strong>Tutors</strong> <strong>India</strong> - Your trusted mentor since 2001<br />
www.tutorindia.com I UK # +44-1143520021, info@tutorsindia.com<br />
Page 12 of 172
Change language